Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

ConditionLymphoma, Non-Hodgkin

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-80

SponsorThe First People's Hospital of Changzhou

About this trial

The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy

Disqualifiers

patients refuse the therapy or have no tolerance for the therapy

Trial design

Design model

Parallel

Treatments tested in this trial

Cytokine-induced killer cells (CIK)
Biological/Vaccine
Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.

Treatment groups

1,000 Participants

are divided into 2 treatment groups

Group A: regular chemotherapyNo intervention 0 interventions

Group B: CIK regimenExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Progression-Free-Survival (PFS)

Time frame

1 month

Secondary outcomes

Overall Survival (OS)

Time frame

1 month

Other outcomes

Lactic Dehydrogenase (LDH)

Time frame

1 month

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The First People's Hospital of Changzhou

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: